Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Annexon advances GBS and GA programs; BLA for tanruprubart expected Q4 2026

Aug 12, 2026, 6:10 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Near-term catalysts (BLA timing, ARCHER II data cadence) and improved liquidity (credit facility, cash runway) can reduce execution risk and potentially drive a re-rating if milestones meet expectations.

AI summary

What happened, with direct paths to the underlying reporting

Annexon reports Q2 2026 results and progress across its C1q programs. Tanruprubart shows potential first-in-class GBS therapy with a Q4 2026 BLA submission; vonaprument ARCHER II expects Month 15 data in 2026 and Month 24 in 2027. A $200M credit facility extends runway into 2028 and ANX1502 POC CAD data arrive Fall 2026.

Tanruprubart BLA submission expected Q4 2026. Potential first targeted GBS therapy.
Vonaprument ARCHER II Month 15 on track. Month 24 readout in 2027.
ANX1502 POC CAD data due Fall 2026. First-in-kind oral C1 inhibitor.
Credit facility up to $200M; runway extended into 2028.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Annexon advances GBS and GA programs; BLA for tanruprubart expected Q4 2026

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)